GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
translation-mRNA display selection platform. These cyclic peptides show preferential binding to the GTP-bound state of K-Ras(G12D) over the GDP-bound state and block Ras-Raf interaction. A co-crystal structure of peptide KD2 with K-Ras(G12D)·GppNHp reveals that this peptide binds in the Switch II groove region with concomitant opening of the Switch II loop and a 40° rotation of the α2 helix, and that a threonine residue (Thr10) on KD2 has direct access to the mutant aspartate (Asp12) on K-Ras. Replacing this threonine with non-natural amino acids afforded peptides with improved potency at inhibiting the interaction between Raf1-RBD and K-Ras(G12D) but not wildtype K-Ras. The union of G12D over wildtype selectivity and GTP state/GDP state selectivity is particularly desirable, considering that oncogenic K-Ras(G12D) exists predominantly in the GTP state in cancer cells, and wildtype K-Ras signaling is important for the maintenance of healthy cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, these compounds have no discernable effect on wild-type KRAS, exemplifying the distinct features of the GTP-bound state of KRAS mutants174.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [174]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These include DARPins [71], cyclic peptides [72], KRAS–RAF protein–protein interaction inhibitors [73], and KRAS–GAP molecular glue-based approaches [74].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [72]
In the citing paper
“In 2020, Zhang et al.174 identified three cyclic peptide ligands that are unique in that they bind preferentially within the switch 2 groove of KRASG12D-GTP and inhibit its interaction with RAF proteins.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [174]
In the citing paper
“cyclic peptide scaffolds have been reported to bind to KRASG12D and inhibit its interaction with CRAF at high nanomolar concentrations, albeit currently lacking cellular activity (32).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Self-citationThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Physiological concentrations of purines and pyrimidines
Traut, T. W. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928361 · Cited by 1,867
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · cited 1×
“2,3 As a result, K-Ras(G12D) is enriched in its GTP-bound, signaling-competent state, given the near 10-fold higher concentration of GTP than GDP inside the cell.”
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641 · cited 1×
“2,3 As a result, K-Ras(G12D) is enriched in its GTP-bound, signaling-competent state, given the near 10-fold higher concentration of GTP than GDP inside the cell.”
Self-citationMaurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Understanding Cell Penetration of Cyclic Peptides
Dougherty, P. G., Sahni, A., & Pei, D. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00008 · Cited by 570
Cited by
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
“Indeed, recently cyclic peptide scaffolds have been reported to bind to KRASG12D and inhibit its interaction with CRAF at high nanomolar concentrations, albeit currently lacking cellular activity (32).”
BackgroundBond, M. J., & Crews, C. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00011j · Cited by 221
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00368-w · Cited by 158
Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S)
Zhang, Z., Guiley, K. Z., & Shokat, K. M. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01065-9 · Cited by 153
Self-citationKRAS is vulnerable to reversible switch-II pocket engagement in cells
Vasta, J. D., Peacock, D. M., Zheng, Q., Walker, J. A., Zhang, Z., Zimprich, C. A., Thomas, M. R., Beck, M. T., Binkowski, B. F., Corona, C. R., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00985-w · Cited by 115
“Studies using engineered proteins and cyclic peptides to probe the SII-P of KRAS have revealed the dynamic nature of this pocket and support the possibility that KRAS − GTP may adopt conformations favorable to SII-P engagement 13–17 .”
Self-citationOhta, A., Tanada, M., Shinohara, S., Morita, Y., Nakano, K., Yamagishi, Y., Takano, R., Kariyuki, S., Iida, T., Matsuo, A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c07145 · Cited by 121
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Bannoura, S. F., Uddin, M. H., Nagasaka, M., Fazili, F., Hallak, M. N. A., Philip, P. A., El‐Rayes, B. F., & Azmi, A. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09990-2 · Cited by 122
Cyclic Peptide Screening Methods for Preclinical Drug Discovery
Li, X., Craven, T. W., & Levine, P. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01077 · Cited by 96
Selective and noncovalent targeting of RAS mutants for inhibition and degradation
Teng, K. W., Tsai, S. T., Hattori, T., Fedele, C., Koide, A., Yang, C., Hou, X., Zhang, Y., Neel, B. G., O’Bryan, J. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22969-5 · Cited by 87
“2 C-terminal to the VHL domain (1-213) with a SSSSG linker and N-terminal HA tag (YPYDVPDYA) following a published design34.”
BackgroundDirecting evolution of novel ligands by mRNA display
Kamalinia, G., Grindel, B. J., Takahashi, T. T., Millward, S. W., & Roberts, R. W. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00160d · Cited by 101
Sakamoto, K., Masutani, T., & Hirokawa, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78712-5 · Cited by 85
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 82
“A 16-mer cyclic peptide, screened from a naïve library, binds to non-switch-region of Cdc42 at nanomolar affinity and inhibits RAS-driven tumor cell proliferation and invasion in a Cdc42-dependent manner.299 Through an integrative approach of mRNA display, in vitro translation, and unnatural amino acid substitution, a…”
BackgroundStrain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
Zheng, Q., Zhang, Z., Guiley, K. Z., & Shokat, K. M. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01565-w · Cited by 88
Self-citationZhou, Y., Zou, Y., Yang, M., Mei, S., Liu, X., Han, H., Zhang, C.-D., & Niu, M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c12075 · Cited by 79
Selection of Nucleotide-Encoded Mass Libraries of Macrocyclic Peptides for Inaccessible Drug Targets
Colas, K., Bindl, D., & Suga, H. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00422 · Cited by 80
Self-citationDrugging the Undruggable: Advances on RAS Targeting in Cancer
Molina-Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 71
“A cyclic peptide that selectively blocks KRAS-G12D in the GTP-bound state has also been identified [123].”
BackgroundA hybrid quantum computing pipeline for real world drug discovery
Li, W., Yin, Z., Li, X., Ma, D., Yi, S., Zhang, Z., Zou, C., Bu, K., Dai, M., Yue, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67897-8 · Cited by 67
“However, in the current landscape, the involvement of quantum computing in drug discovery is primarily restricted to conceptual validation, with minimal integration into real world drug design 19–24 .”
BackgroundSelf-citationSimultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles
Yu, Z., He, X., Wang, R., Xu, X., Zhang, Z., Ding, K., Zhang, Z., Tan, Y., & Li, Z. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05899 · Cited by 63
Self-citationKRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zhang, Z., Zhang, H., Liao, X., & Tsai, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147676 · Cited by 82
Self-citationTackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics
Swenson, C., Mandava, G., Thomas, D. M., & Moellering, R. E. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00423 · Cited by 61
Shi, J., Chen, Y., Peng, C., Kuang, L., Zhang, Z., Li, Y., & Huang, K. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.027545 · Cited by 48
Self-citationIdentification of Covalent Cyclic Peptide Inhibitors in mRNA Display
Iskandar, S. E., Chiou, L. F., Leisner, T. M., Shell, D. J., Norris-Drouin, J. L., Vaziri, C., Pearce, K. H., & Bowers, A. A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04833 · Cited by 45
Li, J., Yanagisawa, K., & Akiyama, Y. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae417 · Cited by 50
“The RaPID system has designed novel cyclic peptides for complex therapeutic targets, including a high-affinity binder to the osteoporosis target PlexinB1 [18],an inhibitor of the ubiquitin-protein ligase E6AP [17], and a selective inhibitor of the oncogenic K-Ras [19].”
BackgroundDiscovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling
Lim, S., Boyer, N. C., Boo, N., Huang, C., Venkatachalam, G., Juang, Y.-C. A., Garrigou, M., Kaan, H. Y. K., Duggal, R., Peh, K. M., et al. (2021) · Chemical Science · doi:10.1039/d1sc05187c · Cited by 39
Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors
Akkapeddi, P., Hattori, T., Khan, I. M., Glasser, E., Koide, A., Ketavarapu, G., Whaby, M., Zuberi, M., Teng, K. W., Lefler, J. E., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302485120 · Cited by 40
“Zhang et al. have developed cyclic peptides that bind dominantly to the GTP-bound state of KRAS(G12D) as well as those bind to both GTP-and GDP-bound states (9).”
Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor
Buyanova, M. Y., Cai, S., Cooper, J. K., Rhodes, C. A., Salim, H., Sahni, A., Upadhyaya, P., Yang, R., Sarkar, A., Li, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01130 · Cited by 41
RAS degraders: The new frontier for RAS-driven cancers
Escher, T. E., & Satchell, K. J. F. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.017 · Cited by 40
Cyclisation strategies for stabilising peptides with irregular conformations
Vu, Q. N., Young, R., Sudhakar, H. K., Gao, T., Huang, T., Tan, Y. S., & Lau, Y. H. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00098e · Cited by 37
Li, L., Liu, J., Yang, Z., Zhao, H., Deng, B., Ren, Y., Mai, R., Huang, J., & Chen, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114243 · Cited by 34
Membrane Permeability in a Large Macrocyclic Peptide Driven by a Saddle-Shaped Conformation
Faris, J. H., Adaligil, E., Popovych, N., Ono, S., Takahashi, M., Nguyen, H. Q., Plise, E. G., Taechalertpaisarn, J., Lee, H., Koehler, M. F. T., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c10949 · Cited by 35
A Sos proteomimetic as a pan-Ras inhibitor
Hong, S. H., Yoo, D. Y., Conway, L. P., Richards-Corke, K. C., Parker, C. G., & Arora, P. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101027118 · Cited by 36
“Recent efforts to engage the Ras G12C (5, 6) and the G12D isoforms (7, 8) suggest that targeted screens may afford small molecules and peptide macrocycles as potential leads.”
BackgroundGarrigou, M., Sauvagnat, B., Duggal, R., Boo, N., Gopal, P., Johnston, J. M., Partridge, A. W., Sawyer, T. K., Biswas, K., & Boyer, N. C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00154 · Cited by 36
Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
Pandey, D., Chauhan, S. C., Kashyap, V. K., & Roy, K. K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116771 · Cited by 32
Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods
Kulkarni, A. M., Kumar, V., Parate, S., Lee, G., Yoon, S., & Lee, K. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031309 · Cited by 33
“A cyclic peptide–KD2 showing binding to active state KRAS-G12D was identified [12].”
BackgroundA cyclic peptide toolkit reveals mechanistic principles of peptidylarginine deiminase IV regulation
Bertran, M. T., Walmsley, R., Cummings, T., Aramburu, I. V., Benton, D. J., Mora-Molina, R., Assalaarachchi, H., Chasampalioti, M., Swanton, T., Joshi, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53554-1 · Cited by 30
“Given the propensity of cyclic peptides to exhibit high selectivity 45,46 , we reasoned that our lead peptide, PADI4_ 3 , might be selective for PADI4.”
Self-citationErlanson, D. A., & Webster, K. R. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.02.010 · Cited by 30
Selection for constrained peptides that bind to a single target protein
King, A. M., Anderson, D. A., Glassey, E., Segall-Shapiro, T. H., Zhang, Z., Niquille, D. L., Embree, A., Pratt, K., Williams, T. L., Gordon, D. B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26350-4 · Cited by 30
Self-citationBansod, S., Dodhiawala, P. B., & Lim, K. (2021) · Cancers · doi:10.3390/cancers13215481 · Cited by 31
“The discovery of cyclic peptide scaffolds that specifically bind KRASG12D oncoprotein is extremely exciting, but these compounds are still being optimized to allow cell permeability [11].”
BackgroundHydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
Wright, K. M., DiNapoli, S. R., Miller, M. S., Azurmendi, P. A., Zhao, X., Yu, Z., Chakrabarti, M., Shi, W., Douglass, J., Hwang, M. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40821-w · Cited by 35
Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors
Zhou, X., Ji, Y., & Zhou, J. (2023) · Molecules · doi:10.3390/molecules28083615 · Cited by 29
“developed a bifunctional small molecular ligand (Figure 5, Compound-12), which was able to serve as a molecular glue to promote the association between cyclophilin A and GTP-bound Ras, which disrupted the interaction with B-Raf.”
BackgroundInfluentialSmall-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
Hyun, S., & Shin, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212142 · Cited by 29
“described the discovery of GTPbound state selective cyclic peptide ligands to KRASG12D using the Random non-standard Peptides Integrated Discovery (RaPID) platform.[22] Co-crystal structure confirmed that the cyclic peptide ligand, KD2, occupied both the Switch II groove (SIIG) and Switch II pocket (SIIP) through the…”
MethodHu, Z., & Martí, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213865 · Cited by 25
“In particular, several strategies have been proposed for targeting KRAS-G12D, such as indole-based inhibitors (BI-2852) of the Switch-I/II pockets [28,29], the piperazine-based compound TH-Z835 for ASP12 [30], the KRAS allosteric ligand KAL-21404358 targeting the site PRO110 [31], a multivalent small molecule named 31…”
BackgroundEliminating oncogenic RAS: back to the future at the drawing board
Steffen, C. L., Kaya, P., Schaffner‐Reckinger, E., & Abankwa, D. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221343 · Cited by 24
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
Kirschner, T., Müller, M. P., & Rauh, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02403 · Cited by 24
Targeting RAS in neuroblastoma: Is it possible?
Lin, L., Miao, L., Lin, H., Cheng, J., Li, M., Zhuo, Z., & He, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108054 · Cited by 24
Utilization of macrocyclic peptides to target protein-protein interactions in cancer
Yang, J., Zhu, Q., Wu, Y., Xiao-juan, Q., Liu, H., Jiang, B., Ge, D., & Song, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.992171 · Cited by 27
Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
Wang, X., Wu, J., Xiao, A., Wang, J., & Tian, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02364-0 · Cited by 29
“Numerous KRAS-targeting cyclic peptides have been developed, including Cyclorasin 9 A/Cyclorasin 9 A5 [148], KD2 [149], KRpep2/KRpep2D [150], Cyclora-sin B4-27 [151] and LUNA18 [137–140].”
One-Pot In Vitro Ribosomal Synthesis of Macrocyclic Depsipeptides
Nagano, M., Huang, Y., Obexer, R., & Suga, H. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00466 · Cited by 21
Self-citationLi, C., Zhao, N., An, L., Dai, Z., Chen, X., Yang, F., You, Q., Di, B., Hu, C., & Xu, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.013 · Cited by 20
Schneider, A. F. L., Kallen, J. A., Ottl, J., Reid, P., Ripoche, S., Ruetz, S., Stachyra, T., Hintermann, S., Dumelin, C. E., Hackenberger, C. P. R., et al. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00056j · Cited by 20
Targeting the “undruggable” RAS with biologics
Whaby, M., Khan, I., & O’Bryan, J. P. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.006 · Cited by 24
Mahran, R., Kapp, J. N., Valtonen, S., Champagne, A., Ning, J., Gillette, W., Stephen, A. G., Hao, F., Plückthun, A., Härmä, H., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00315 · Cited by 23
Komatsu, Y., Terasaka, N., Sakai, K., Mihara, E., Wakabayashi, R., Matsumoto, K., Hilvert, D., Takagi, J., & Suga, H. (2021) · iScience · doi:10.1016/j.isci.2021.103302 · Cited by 18
Self-citationMathiesen, I. R., Calder, E. D. D., Kunzelmann, S., & Walport, L. J. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01388-9 · Cited by 21
Lu, X., Jin, J., Wu, Y., Liu, X., Liang, X., Lin, J., Sun, Q., Qin, J., Zhang, W., & Luan, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21993 · Cited by 17
“Zhang et al. 134 identified three cyclic peptides preferentially binding to the GTP ‐ bound state of KRAS G12D , and another cyclic peptide, NKTP ‐ 3, can simultaneously target NRP1 and KRAS G12D .”
BackgroundSelected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway
Harwood, S. J., Smith, C. R., Lawson, J. D., & Ketcham, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087373 · Cited by 17
“However, disrupting the RAS:RAF PPI is an intriguing approach to perturbing irregular KRAS signaling, and other researchers have focused on the s f cyclic peptid s [94,95] or organometallic [96] compounds to dis upt the RAS:RAF PPI.”
BackgroundIdentification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles
Vetma, V., Puoti, I., Karolak, N. K., Chakraborti, S., Diers, E., Girardi, E., Khan, S., Kidd, G., Kropatsch, K., McLennan, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c10354 · Cited by 21
Chen, J., Wang, J., Wang, W., Zhao, L., Jin, H., & Hu, G. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c07583 · Cited by 19
Kage, M., Hayashi, R., Matsuo, A., Tamiya, M., Kuramoto, S., Ohara, K., Irie, M., Chiyoda, A., Takano, K., Ito, T., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117830 · Cited by 16
SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers
Lilja, J., Kaivola, J., Conway, J. R. W., Vuorio, J., Parkkola, H., Roivas, P., Dibus, M., Chastney, M. R., Varila, T., Jacquemet, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52326-1 · Cited by 15
Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains
Nomura, T. K., Heishima, K., Sugito, N., Sugawara, R., Ueda, H., Akao, Y., & Honda, R. P. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.013 · Cited by 16
Non‐Canonical Amino Acids for Engineering Peptides and Proteins with new Functions
Zhou, K. Z. Q., & Obexer, R. (2024) · Israel Journal of Chemistry · doi:10.1002/ijch.202400006 · Cited by 14
Ostrem, J. M. L., Peters, U., & Shokat, K. M. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01691-5 · Cited by 13
Self-citationShen, Y., Zhang, X., Zhang, L.-Y., Zhang, Z., Lyu, B., Lai, Q., Li, Q., Zhang, Y., Ying, J., & Song, J. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-208974 · Cited by 14
Self-citationProbing the KRas Switch II Groove by Fluorine NMR Spectroscopy
Peacock, D. M., Kelly, M. J. S., & Shokat, K. M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00566 · Cited by 8
Self-citationOyedele, A.-Q. K., Owolabi, N., Odunitan, T. T., Ajibare, A. C., Jimoh, R. O., Abdulazeez, W. O., Titilayo, M. B.-H., Soares, A. S., Adekola, A. T., Abdulkareem, T. O., et al. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101170 · Cited by 9
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 16
KRAS Inhibition in Pancreatic Ductal Adenocarcinoma
Pradeep, R., Isbeih, N. J., Abraham, F. F., Noori, E., Yeung, Z. P., & Kundranda, M. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020873 · Cited by 9
“The interaction between KRAS and SOS1 is effectively blocked by the compound KRpep-2d, thereby preventing RAF-MEK-ERK activation and downregulating pERK signaling in KRAS G12D mutant cells [69].”
Structure–activity relationship of ipglycermide binding to phosphoglycerate mutases
Wiedmann, M. M., Dranchak, P. K., Aitha, M., Queme, B., Collmus, C. D., Kashipathy, M. M., Kanter, L., Lamy, L., Rogers, J. M., Tao, D., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100628 · Cited by 8
“Cyclic peptides are increasingly leading to the discovery of novel binding surfaces to modulate protein function and elucidate protein dynamics, as recently demonstrated for lysine-specific demethylase one and a missense-mutated K-Ras(G12D)-Raf interaction (40, 41).”
BackgroundSelf-citationIlter, M., Kaşmer, R., Jalalypour, F., Atılgan, C., Topcu, O., Karakaş, N., & Şensoy, Ö. (2022) · eLife · doi:10.7554/elife.79747 · Cited by 7
Alshahrani, M., Parikh, V., Foley, B., Hu, G., & Verkhivker, G. M. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp00966a · Cited by 7
Recent Advances in Non‐Standard Macrocyclic Peptide Ligand Discovery using mRNA Display
Yin, Y., & Hipolito, C. J. (2024) · Israel Journal of Chemistry · doi:10.1002/ijch.202300167 · Cited by 7
Peptide inhibitors targeting Ras and Ras-associated protein–protein interactions
Han, D., Li, A., Zhu, L., Zhuang, C., Zhao, Q., & Zou, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116878 · Cited by 7
Contract to kill: GNAS mutation
Raut, P., Mathivanan, P., Batra, S. K., & Ponnusamy, M. P. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02247-4 · Cited by 6
“…cyclic peptide inhibitor for KRAS G12D – effector interaction, cyclic peptide ligands of KRAS G12D selective to GTP-state, KRAS G12C inhibitor, Adagrasib (MRTX849), which targets the mutant cysteine in GDP-bound state and KRAS -dependent pathways have promoted KRAS to the druggable status [85– 88].”
Peptide Drug DiscoveryRaison d’Etre: Engineering Mindset, Design Rules and Screening Tools
Sawyer, T. K., & Biswas, K. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ch001 · Cited by 9
Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy
Qin, W., Liu, Z., Huang, M., Liang, L., Gan, Y., Huang, Z., Huang, J., & Wei, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041425 · Cited by 5
“…et al. identified a cyclic peptide ligand, KD2 (Table 1), that selectively binds to KRas in a highly dynamic pocket near the switch II region (SIIP). displacement of the 2 helix and the Switch II loop, effectively blocking Ras-Raf interactions and inhibiting the proliferation of cancer cells [36].”
Structure–activity relationships of KRAS-G12D inhibitors for pancreatic cancer
Suyal, C., Mangala, S. S., Kishore, A., & Kini, S. G. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104396 · Cited by 7
Zhang, Q., Geng, Y., 陈海涛, Ni, J., Guan, L., Zhai, D., Wang, Y., Xu, S., Niu, M., Zheng, L., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02435 · Cited by 4
Han, D., Zhou, Y., Zhang, K., Gai, C., Zhang, P., Chai, X., Zhuo, X., Zhao, Q., Zou, Y., & Zhu, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117568 · Cited by 5
Hu, Z., & Martí, J. (2024) · Molecular Physics · doi:10.1080/00268976.2024.2316883 · Cited by 5
Kidane, M., Hoffman, R. M., Wolfe-Demarco, J. K., Huang, T.-Y., Teng, C.-L., Samanta, S., Lira, L. M. G., Lin‐Jones, J., Pallares, G., Lamerdin, J. E., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00450 · Cited by 3
Sharma, A. K., Dyba, M. D., Tonelli, M., Smith, B., Gillette, W., Esposito, D., Nissley, D. V., McCormick, F. P., & Maciag, A. E. (2021) · Biomolecular NMR Assignments · doi:10.1007/s12104-021-10050-7 · Cited by 3
Golosov, A. A., Flyer, A. N., & Monovich, L. G. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ch008 · Cited by 4
Peptides That Block RAS-p21 Protein-Induced Cell Transformation
Pincus, M. R., Lin, B., Patel, P. R., Gabutan, E. C., Zohar, N., & Bowne, W. B. (2023) · Biomedicines · doi:10.3390/biomedicines11020471 · Cited by 3
“The striking feature of these comparisons is that in the KD2-bound structure, there is a major movement of the α-2 helix by about 40◦ in the switch 2 domain and the peptide binds deeply in this groove between t is α-2 helix and the switch 2 loop [29].”
BackgroundMethodInfluentialBostancioglu, S. M., & Acar, A. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07137-y · Cited by 3
Protein State‐Dependent Chemical Biology
Scott, K. A., Zhang, T. L., Xi, S. Y., Ngo, B., & Vinogradova, E. V. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202200101 · Cited by 3
mRNA Display and Its Growing Potential in the Discovery of De Novo Therapeutic Peptide Candidates
Helmling, C., & Cunningham, C. N. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ch002 · Cited by 3
Discovering and targeting dynamic drugging pockets of the oncogene KRAS-G12DPreprint
Hu, Z., & Martı́, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.01.498403 · Cited by 2
Covalent inhibitors of K-Ras G12S, G12R, and G12D
Zhang, Z., & Shokat, K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00024-3 · Cited by 3
Self-citationZhou, J., Fang, Z., Zhang, W., Rao, G.-W., & Zheng, Q. (2025) · Mini-Reviews in Organic Chemistry · doi:10.2174/0118756298391640250731025705 · Cited by 1
Shkil, D. O., Eliseev, I. A., Ivanov, R. A., & Balakin, K. V. (2026) · Russian Chemical Bulletin · doi:10.1007/s11172-026-4863-z · Cited by 1
Nie, Q., Li, X., Fang, X., Fan, J., Yang, X., Zhang, G., Li, Y., & Li, Y. (2026) · Chinese Journal of Chemistry · doi:10.1002/cjoc.70673 · Cited by 1
Aisyah, A., Tan, M. I., & Fibriani, A. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00587 · Cited by 1
The evolution of RAS structural biology
Simanshu, D. K., & Knox, J. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00012-7 · Cited by 1
Motif-guided identification of KRAS-interacting proteins
Wu, S., Gao, X., Wu, D., Liu, L., Yao, H., Meng, X., Zhang, X., & Bai, F. (2024) · BMC Biology · doi:10.1186/s12915-024-02067-w · Cited by 1
Ilter, M., Kaşmer, R., Jalalypour, F., Atılgan, C., Topcu, O., Karakaş, N., & Şensoy, Ö. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.24.489309 · Cited by 1
“It is important to point that Y32 adopted 80° in the crystal structure of allosteric inhibitor-bound KRAS4BG12D (PDB ID:6WGN) Zhang et al. (2020), where the residue was exposed and far from the nucleotide-binding pocket as the distance measured between the side-chain of Y32 and Pγ atom of GTP was…”
BackgroundStrain-release alkylation of Asp12 enables mutant selective GTP-state targeting of K-Ras(G12D)Preprint
Zheng, Q., Zhang, Z., Guiley, K. Z., & Shokat, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.01.547359 · Cited by 1
Self-citationKano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
“These include DARPins [71], cyclic peptides [72], KRAS–RAF protein–protein interaction inhibitors [73], and KRAS–GAP molecular glue-based approaches [74].”
Metadata
- Authors
- Zhang, Z., Gao, R., Hu, Q., Peacock, H., Peacock, D. M., Dai, S., Shokat, K. M., & Suga, H.
- Affiliations
- Howard Hughes Medical Institute (US)
- The University of Tokyo (JP)
- Corresponding author
- Shokat, Kevan M.
- Suga, Hiroaki
- ORCID
- Venue
- ACS Central Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-09-23
- Volume
- 6
- Issue
- 10
- Pages
- 1753-1761
- ISSN
- 2374-7943 (ISSN-L)
- 2374-7951
- PMC
- PMC7596874
- OpenAlex
- W3089129315
- Cited by
- 124
- References
- 47
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 25 · 2023: 20 · 2022: 22 · 2021: 25 · 2020: 1
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- ACS Central Science (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (1R01CA244550)
- Damon Runyon Cancer Research Foundation (DRG-2229-15, DRG-2281-17)
- Samuel Waxman Cancer Research Foundation
- Mark Foundation For Cancer Research (SU2C)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12D, Raf, Ras-Raf interaction, cyclic peptide ligands, unnatural amino acids, oncogenic Ras
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.